➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,352,717

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,352,717 protect, and when does it expire?

Patent 6,352,717 protects FORTOVASE and is included in one NDA.

Protection for FORTOVASE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in thirty-four countries.

Summary for Patent: 6,352,717
Title: Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses
Abstract:The present invention provides a process for encapsulating a shear sensitive fill mass which contains a pharmaceutical active agent or nutrient, characterized in that said fill mass is heated and subsequently cooled, prior to the encapsulation. The invention also provides capsules comprising shear sensitive fill material obtained by the said process which have a high and constant dissolution rate.
Inventor(s): Alex; Rainer (Weil am Rhein, DE), Gerhards; Jurgen (Arlesheim, CH), Kraemer-Pittrof; Ingeborg (Rheinfelden, DE), Oeschger; Richard (Rheinsulz, CH), Rades; Thomas (Dunedin, NZ)
Assignee: Hoffman-La Roche Inc. (Nutley, NJ)
Application Number:09/440,731
Patent Claim Types:
see list of patent claims
Dosage form; Process; Formulation;

Drugs Protected by US Patent 6,352,717

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,352,717

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98121831Nov 17, 1998

International Family Members for US Patent 6,352,717

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 020013   Start Trial
Austria 274895   Start Trial
Australia 1775100   Start Trial
Australia 751446   Start Trial
Brazil 9915444   Start Trial
Canada 2350943   Start Trial
China 1172649   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.